Your browser doesn't support javascript.
loading
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
Lin, Chenyu; Sajeev, Gautam; Stiff, Patrick J; Brunstein, Claudio G; Cutler, Corey; Sanz, Guillermo; Lindemans, Caroline A; Rezvani, Andrew R; Hanna, Rabi; Koh, Liang Piu; Maziarz, Richard T; Hwang, William Y K; Song, Yan; Liu, Qing; Manghani, Rocio; Sivaraman, Smitha; Signorovitch, James; Horwitz, Mitchell E; Sung, Anthony D.
Affiliation
  • Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina.
  • Sajeev G; Analysis Group, Inc, Boston, Massachusetts.
  • Stiff PJ; Division of Hematology and Oncology, Loyola University Medical Center, Chicago, Illinois.
  • Brunstein CG; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota; Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio.
  • Cutler C; Division of Stem Cell Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sanz G; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; CICERONC, Instituto de Salud Carlos III, Madrid, Spain; IIS La Fe, Valencia, Spain.
  • Lindemans CA; Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Rezvani AR; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California.
  • Hanna R; Department of Pediatric Hematology Oncology and Bone Marrow Transplantation, Cleveland Clinic Children's Hospital, Cleveland, Ohio.
  • Koh LP; Department of Hematology-Oncology, National University Cancer Institute, Singapore.
  • Maziarz RT; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
  • Hwang WYK; Department of Haematology, National Cancer Centre Singapore; Department of Haematology, Singapore General Hospital; Cancer and Stem Cell Biology, Duke-NUS Medical School.
  • Song Y; Analysis Group, Inc, Boston, Massachusetts.
  • Liu Q; Analysis Group, Inc, Boston, Massachusetts.
  • Manghani R; Gamida Cell, Boston, Massachusetts.
  • Sivaraman S; Gamida Cell, Boston, Massachusetts.
  • Signorovitch J; Analysis Group, Inc, Boston, Massachusetts.
  • Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina.
  • Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina. Electronic address: anthony.sung@duke.edu.
Transplant Cell Ther ; 29(1): 52.e1-52.e9, 2023 01.
Article in En | MEDLINE | ID: mdl-36179986
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Hematologic Neoplasms Type of study: Clinical_trials / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Transplant Cell Ther Year: 2023 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Hematologic Neoplasms Type of study: Clinical_trials / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Transplant Cell Ther Year: 2023 Document type: Article Country of publication: Estados Unidos